Sugi Predict

Sugi Predict / Compounds / SCHEMBL6495154

SCHEMBL6495154

SCHEMBL6495154

CCCCS(=O)(=O)Nc1ccc(Cn2c(C)nc3ccc(C(=O)O)nc32)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 6/20 0.50
▸ ALDH1A1 P00352 4/20 0.43
▸ MAPT P10636 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HPGD P15428 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ HTT P42858 2/20 0.38
▸ EPHX2 P34913 1/20 0.36
▸ NR1H4 Q96RI1 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PDE5A O76074 2/20 0.35
▸ PDE1A P54750 2/20 0.35
▸ PDE1B Q01064 2/20 0.35
▸ PDE3B Q13370 2/20 0.35
▸ PDE1C Q14123 2/20 0.35
▸ PDE3A Q14432 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495256 0.91 PPARG (0.49) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6298620 0.87 ALDH1A1 (0.44) PPARGALDH1A1MAPTSMN1; SMN2EPHX2
SCHEMBL6500342 0.86 PPARG (0.48) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6301721 0.85 ALDH1A1 (0.45) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6301487 0.85 ALDH1A1 (0.44) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6299191 0.84 ALDH1A1 (0.46) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6493802 0.84 ALDH1A1 (0.52) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6504715 0.82 PPARG (0.60) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6304950 0.82 ALDH1A1 (0.56) PPARGALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL6299056 0.81 PPARG (0.69) PPARGALDH1A1MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 — — US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 — — US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 — — US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PPARG 858/4885ALDH1A1 476/4885MAPT 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.